Related Experiment Video

Updated: Jul 9, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of

Daniel Levin1, Ellen Lewis1, Sylvia McCulloch1

  • 1Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.

Leukemia & Lymphoma
|December 6, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

2.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

447

Related Experiment Videos

Last Updated: Jul 9, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

2.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

447

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195

Articles linked to this work by shared authors, journal, and citation graph.

Clinical Experience With RIST-Based Multimodality Therapy in Relapsed Ewing Sarcoma: A Descriptive Single-center Case Series.

Journal of pediatric hematology/oncology·2026

Terminal discharge of the imminently dying from hospital to home: A realist evaluation.

Palliative medicine·2026

Challenging the 4-h premedication regimen for iodinated contrast allergy: A multicenter retrospective study.

The American journal of emergency medicine·2026

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Leukemia·2026

Autoantibodies and Relapse of Systemic Sclerosis After Autologous Hematopoietic Cell Transplantation.

The Journal of rheumatology·2026

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

Nature medicine·2026

PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study.

Leukemia & lymphoma·2026

Immunoglobulin kinetics and infection patterns across venetoclax-based regimens in chronic lymphocytic leukemia.

Leukemia & lymphoma·2026

Oral azacitidine as time-limited, PCR-dependent maintenance in acute myeloid leukemia with inv(16): two case reports.

Leukemia & lymphoma·2026

Long-term mental health service utilization among patients with diffuse large B-cell lymphoma: a population-based study.

Leukemia & lymphoma·2026

Emerging drug profile: bexobrutideg.

Leukemia & lymphoma·2026

Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.

Leukemia & lymphoma·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us